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Abstract
Background: The Korea Hypertension Fact Sheet 2018 aims to overview the magnitude and management status of
hypertension, and their trends in Korea.
Methods: The Hypertension Epidemiology Research Group analyzed the 1998–2016 Korea National Health and
Nutrition Examination Survey data and the 2002–2016 Korea National Health Insurance Big Data.
Results: The population average of systolic/diastolic blood pressure was 118/77 mmHg among Korean adults (age
30+) in 2016, showing little change in recent 10 years. However, the number of people with hypertension increased
steadily, exceeding 11 million. The number of people diagnosed with hypertension increased from 3 million in 2002
to 8.9 million in 2016. The number of people using antihypertensive medication increased from 2.5 million in 2002
to 8.2 million in 2016. However, only 5.7 million people are being treated constantly. Hypertension awareness,
treatment, and control rates increased fast until 2007, but showed a plateau thereafter. More than half of the young
hypertensive patients (30–49 years) did not know about and treat for their hypertension. Among patients prescribed
antihypertensive medications, 45% was elderly people over the age of 65 years, 57% used anti-diabetic or cholesterol-
lowering medications, and 60% were prescribed two or more class of antihypertensive medications simultaneously.
Conclusions: In Korea, the level of hypertension management has considerably improved over the last 20 years. In
order to achieve further improvement in hypertension management status, we need to find the vulnerable subgroups
and develop subgroup-specific intervention strategies. It is also becoming more important to manage hypertensive
patients at older age and those with concurrent chronic diseases.
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Background
Hypertension is not only the most important modifiable
risk factor for cardiovascular and cerebrovascular diseases,
but also the most contributable factor of the disease burden
in the world [1, 2]. In the twenty-first century, mortality
from cardiovascular and cerebrovascular diseases account
for nearly one half of all deaths in the developed region,
and for one quarter in the developing region [3]. In Korea,
cerebrovascular and cardiovascular diseases rank first and
second for mortality as single-organ diseases [4]. Total
medical cost for hypertension was estimated to 2850 billion
Korean won which accounts for 13.4% of medical cost due
to all chronic disorders [5, 6]. This means that controlling
the hypertension is crucial to reducing the overall burden
of disease in society and improving quality of life. To re-
duce and control hypertension, continuous monitoring
of the magnitude and management status of hyperten-
sion should be the first step. Thus the Korean Society
Hypertension (KSH) – Hypertension Epidemiology Re-
search Working Group analyzed national representative
datasets to overview of the magnitude and management
status of hypertension and their trends between 1998
and 2016 in Korea.
Methods
The Korea Hypertension Fact Sheet 2018 analyzed two
national representative datasets. The first one is the
Korea National Health and Nutrition Examination Survey
(KNHANES) from 1998 to 2016. The KNHANES is a na-
tional surveillance system in Korea that assesses the health
and nutritional status of Koreans since 1998 [7]. In the
KNHANES from 1998 to 2016, adults over 30 years of age
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were included in the current analysis. The second one is
the National Health Insurance (NHI) Big Data from 2002
to 2016. The NHI Big Data is a public database on health
care utilization, health screening, socio-demographic vari-
ables, and mortality for the whole population of South
Korea, formed by the National Health Insurance Service
[8]. In the NHI Big Data from 2002 to 2016, people of all
ages were included in the current analysis.
Analysis of the KNHANES from 1998 to 2016
Hypertension is defined as systolic blood pressure (SBP) ≥
140 mmHg, diastolic blood pressure (DBP) ≥ 90 mmHg or
self-reported use of antihypertensive medication. Aware-
ness rate was defined as the proportion of people who re-
ported to be diagnosed with hypertension from physicians
among all people with hypertension. The treatment rate
was defined as the proportion of people using antihy-
pertensive drugs for 20 days or more per month among
all people with hypertension. The control rate was de-
fined as the proportion of people who having SBP <
140 mmHg and DBP < 90 mmHg with antihypertensive
medication, among the all people with hypertension as
well as among the treated people with hypertension. To
evaluate the magnitude and management status of
hypertension excluding the effects of population aging,
an indirect standardization method was used. The in-
direct age standardization is based on the demographics
of the Korean population in 2005 from the Population
and Housing Census performed by Statistics Korea.
Analysis of the NHI big data from 2002 to 2016
The medical service use was defined as any case of person
seeking medical service with diagnosis of essential hyper-
tension at least once a year, and the cases were identified
from the NHI claim database. Treatment of hypertension
was defined as the case of person who receives prescrip-
tion of any antihypertensive medications at least once per
every year. The sustained treatment that reflects persist-
ence was defined as the case of person who receives anti-
hypertensive prescriptions for at least 290 days (80%) per
year. If the prescription of hypertension treatment had
changed several times, the prescription for the longest
duration every year was used as the representative pre-
scription of the patient for the year, and the use of the
medication was classified accordingly. Antihypertensive
medications were classified into diuretics, beta-blockers,
calcium channel blockers, angiotensin receptor blockers,
angiotensin-converting enzyme inhibitors, aldosterone an-
tagonists, alpha-blockers, vasodilators, and others.
Results
Magnitude of hypertension
Among the adult Korean population aged 30 years or
older, age-standardized mean SBP/DBP was 129/82 mmHg
for men and 126/78 mmHg for women in 1998, and 121/
79 mmHg for men and 114.8 for men and 115/74 mmHg
for women in 2016 (Additional files 1 and 2 Page 11).
Over the last 10 years, the age-standardized mean blood
pressure levels remained almost unchanged. The
age-standardized prevalence of hypertension also show lit-
tle change from 29.8% (men 32.4%, women 26.8%) in 1998
to 29.1% (men 35.0%, women 22.9%) in 2016 (Additional
files 1 and 2, page 12). However, due to the rapid popula-
tion aging, the number of people with hypertension has
steadily increased from 7.6 million in 1998 to over 11 mil-
lion recently (Additional files 1 and 2, page 14). Hyperten-
sion prevalence increased with age in both sexes
(Additional files 1 and 2, page 13). But the sex-specific
prevalence was higher in men until the age of 60s, but
higher in women from the age of 70s.
Hypertension management status
Awareness, treatment, and control rates of hypertension,
which are frequently used indicators of hypertension man-
agement, increased all rapidly from 1998 to 2007, but
thereafter remained almost unchanged (Additional files 1
and 2, page 17). The awareness rate increased from 25%
in 1998 to 65% in 2007, and still remained at 65% in 2016.
The treatment rate increased from 22% in 1998 to 59% in
2007 and 61% in 2016. The control rate increased from
5% in 1998 to 41% in 2007 and to 44% in 2016.
In stratifying by sex, hypertension awareness rate in
2016 was 64.9% for men and 66.8% for women (Additional
files 1 and 2, page 18). The treatment rate of hypertension
in 2016 was 60.1% for men and 64.3% for women (Add-
itional files 1 and 2, page 19). Control rate among all
people with hypertension was 43.4% for men and 47.4% in
women, suggesting that 56% of hypertensive patients are
still unable to control their blood pressure (Additional
files 1 and 2, page 20). Control rate among treated people
with hypertension was 71.0% for men and 70.6% in
women (Additional files 1 and 2, page 21). Overall,
women showed better management status of hyperten-
sion compared to men. In age-sex specific analysis, the
younger people with hypertension (30–49 years) in
both sexes still have awareness, treatment, and control
rates below 50% (Additional files 1 and 2, pages 22–24).
Medical service uses for hypertension
The number of people diagnosed with hypertension in
medical institution has increased by about three times
from 3 million in 2002 to 8.9 million in 2016 (Additional
files 1 and 2, page 27). People who receiving antihyper-
tensive prescription also increased more than three
times from 2.5 million in 2002 to 8.2 million in 2016.
However, only 5.7 million people are constantly being
treated in 2016, which is approximately 64% of all hyper-
tensive patients.
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Among people receiving antihypertensive prescription,
the proportion of people aged 65 or older increased
from 34% in 2002 to 46% in 2016 (Additional files 1
and 2, pages 28, 29). The proportion of hypertensive
people who are receiving diabetes or dyslipidemia treat-
ment as well as people receiving antihypertensive pre-
scription also rapidly increased from 25% in 2002 to
57% in 2016 (Additional files 1 and 2, pages 30, 31).
In 2002, 57% of the treated patients were prescribed
single class of antihypertensive medications (Additional
files 1 and 2, pages 32, 33). However, in 2016, only 40%
of the treated patients were prescribed one class of anti-
hypertensive medication, 42% were prescribed two clas-
ses, and 18% were prescribed three or more classes.
Calcium channel blockers have been the most widely
used as single class of antihypertensive medications for a
long time, but the use of angiotensin receptor blockers
has increased rapidly and has been prescribed more than
calcium channel blockers for the first time in 2016
(Additional files 1 and 2, pages 36, 37). The most common
antihypertensive regimen is a combination of calcium
channel blockers and angiotensin blockers (Additional
files 1 and 2, pages 40–43).
Discussion
The Korea Hypertension Fact Sheet 2018 provides an over-
view on the magnitude and management status of hyper-
tension in Korea. Although the population average of blood
pressure has been showing little change in recent 10 years,
the absolute number of people with hypertension increased
steadily, exceeding 11 million due to the population aging.
People who receiving antihypertensive prescription also
increased, but people are constantly being treated is
approximately 64% of all hypertensive patients in 2016.
Hypertension management status in Korea had been greatly
improved until 2007, but thereafter there has been little fur-
ther improvement. Overall, women had a better manage-
ment status of hypertension than men. However, in
younger age groups, both men and women showed lower
levels of hypertension management than other age groups.
To achieve further improvement in hypertension manage-
ment, it is important to increase awareness and treatment
rates for younger people with hypertension. It is another
challenge to manage hypertensive people with old age and
those with concurrent chronic diseases such as diabetes and
dyslipidemia. We also need to develop customized preven-
tion and management strategies which fit various subgroup
characteristics. Emphasizing the importance of persistent
treatment and blood pressure control to prevent complica-
tions and death from hypertension is still a top priority.
Conclusions
In Korea, the level of hypertension management has sub-
stantially improved over the last 20 years. In order to
achieve further improvement in hypertension manage-
ment status and quality of life, we need to find the
vulnerable subgroups and develop subgroup-specific
intervention strategies, suggesting that more carefully
managing hypertensive patients at older age and those
with concurrent chronic diseases.
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